Many patients on long-term antihypertensive treatment consider follow-up visits unnecessary as long as their home blood pressure measurements are normal and drugs can be ordered by phone. Are follow-up visits really needed?
Patients with monoclonal gammopathy of unknown significance (MGUS) are at low risk for progression to plasma cell myeloma (multiple myeloma). Who should take care of these patients: hematologists and oncologists? Or general practitioners?
How do you see the future of internal medicine in Europe? Is there a chance to unify the internal medicine curriculum in all European Union countries? Should we expect European examination and certification in internal medicine?